Skip to main content

Research program to elucidate the molecular biological mechanism of action of NMN started with the Systems Biology Research Organization, a non-profit organization.

Published Date:2018年11月06日 Updated Date:2023年07月21日 研究情報

Shinko Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo; CEO: Megumi Tanaka) has launched a series of life science research programs focusing on the mechanism of action and effects of Nicotinamide Mononucleotide (NMN).

For the press release, please see here.

Your Cart
Your cart is currently empty.
Click here to continue shopping.
Thanks for contacting us! We'll get back to you shortly. 【!】Your registration is not yet complete. A registration confirmation e-mail has been sent to the e-mail address you entered. Please check the contents and complete your registration. Thanks! We will notify you when it becomes available! The max number of items have already been added There is only one item left to add to the cart There are only [num_items] items left to add to the cart